All Stories

  1. Plasma extracellular vesicle microRNAs reflecting the therapeutic effect of the CBP/β-catenin inhibitor PRI-724 in patients with liver cirrhosis
  2. Identifying high-grade serous ovarian carcinoma–specific extracellular vesicles by polyketone-coated nanowires
  3. Data from Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
  4. Data from Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
  5. Data from Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer
  6. Data from Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer
  7. Figure S1-3, Table S1-4 from Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
  8. Figure S1-3, Table S1-4 from Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
  9. Supplementary text from Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
  10. Supplementary text from Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
  11. Table S1, Table S2, Table S3, Table S4, Table S5, Table S6, Table S7, Table S8, Table S9, Table S10, Table S11, Figure S1, Figure S2, Figure S3, Text from Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer
  12. Table S1, Table S2, Table S3, Table S4, Table S5, Table S6, Table S7, Table S8, Table S9, Table S10, Table S11, Figure S1, Figure S2, Figure S3, Text from Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer
  13. Evidence forin vitroextensive proliferation of adult hepatocytes and biliary epithelial cells
  14. Circulating microRNAs: Challenges with their use as liquid biopsy biomarkers
  15. Circulating microRNA profiling for prediction of oncological outcomes in prostate cancer patients following radical prostatectomy
  16. Independent verification of circulating miRNA as diagnostic biomarkers for urothelial carcinoma
  17. Correction: Generation of human hepatic progenitor cells with regenerative and metabolic capacities from primary hepatocytes
  18. Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐lineHelicobacter pylorieradication regimen
  19. Identification of circulating microRNAs as potential biomarkers for hepatic necroinflammation in patients with autoimmune hepatitis
  20. Response to letter regarding: development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication
  21. Serum microRNA as liquid biopsy biomarker for the prediction of oncological outcomes in patients with bladder cancer
  22. Development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication
  23. Superiority of urgent vs early endoscopic hemostasis in patients with upper gastrointestinal bleeding with high-risk stigmata
  24. Extracellular microRNA profiling for prognostic prediction in patients with high‐grade serous ovarian carcinoma
  25. Challenges for Better Diagnosis and Management of Pancreatic and Biliary Tract Cancers Focusing on Blood Biomarkers: A Systematic Review
  26. Comprehensive serum and tissue microRNA profiling in dedifferentiated liposarcoma
  27. Early prediction of COVID‐19 severity using extracellular vesicle COPB2
  28. A novel combination of serum microRNAs for the detection of early gastric cancer
  29. Extracellular miRNAs for the Management of Barrett’s Esophagus and Esophageal Adenocarcinoma: A Systematic Review
  30. Early Prediction of COVID-19 Severity Using Extracellular Vesicles and Extracellular RNAs
  31. Horibe GI bleeding prediction score: a simple score for triage decision-making in patients with suspected upper GI bleeding
  32. Adenosine leakage from perforin-burst extracellular vesicles inhibits perforin secretion by cytotoxic T-lymphocytes
  33. A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy
  34. Peripheral neuropathy from paclitaxel: risk prediction by serum microRNAs
  35. Precision Medicine Approaches to Prevent Gastric Cancer
  36. Efficacy and safety of immediate oral intake in patients with mild acute pancreatitis: A randomized controlled trial
  37. Circulating microRNAs: Next-generation Cancer Detection
  38. Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease
  39. Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma
  40. Serum microRNA profile enables preoperative diagnosis of uterine leiomyosarcoma
  41. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Teprenone in Patients with Alzheimer’s Disease
  42. Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab
  43. Brain metastasis-related microRNAs in patients with advanced breast cancer
  44. Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer
  45. Transcriptomic Dissection of Hepatocyte Heterogeneity: Linking Ploidy, Zonation, and Stem/Progenitor Cell Characteristics
  46. Generation of human hepatic progenitor cells with regenerative and metabolic capacities from primary hepatocytes
  47. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy
  48. Generation of functional human hepatocytes in vitro: current status and future prospects
  49. Serum MicroRNA-Based Risk Prediction for Stroke
  50. Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling
  51. Circulating microRNA‐1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma
  52. Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori–Infected CAPZA1-Overexpressing Cells
  53. Generation of human hepatic progenitor cells with regenerative and metabolic capacities from primary hepatocytes
  54. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma
  55. A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes
  56. Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer
  57. Neutrophil-activating Protein Polymorphism of Helicobacter pylori Determines the Host Risk of Dyspepsia
  58. Diagnostic Ability of Serum microRNA Classification in Diffuse Glioma: A Retrospective Comprehensive Analysis with Case-Control Study
  59. Circulating miRNA panels for specific and early detection in bladder cancer
  60. Clinical and endoscopic findings to assist the early detection of duodenal adenoma and adenocarcinoma
  61. Serum miRNA-based prediction of axillary lymph node metastasis in breast cancer
  62. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression
  63. Integrated extracellular microRNA profiling for ovarian cancer screening
  64. Predicting the risk of peripheral neuropathy by the combination of four serum microRNAs
  65. Deregulation of CAPZA1 expression increase risk of gastric carcinogenesis.
  66. Gastric cancer: evidence boosts Helicobacter pylori eradication
  67. Absence of high-risk stigmata predicts good prognosis even in severely anemic patients with suspected acute upper gastrointestinal bleeding
  68. Extracellular microRNAs and oxidative stress in liver injury: a systematic mini review
  69. Helicobacter pylorieradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk
  70. A tissue microRNA signature that predicts the prognosis of breast cancer in young women
  71. Enteric Glial Dysfunction Evoked by Apolipoprotein E Deficiency Contributes to Delayed Gastric Emptying
  72. Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens
  73. Circulating microRNAs as potential biomarkers to detect transformation of Barrett’s oesophagus to oesophageal adenocarcinoma
  74. Burden of impaired sleep quality on work productivity in functional dyspepsia
  75. Abstract 5678: Novel serum microRNAs that enable liquid biopsy for colorectal cancer: validation study of large cohort
  76. Impact of Functional Dyspepsia and ITS Concomitant Symptoms on the Loss of Work Productivity
  77. Serum Micrornas can Detect Colorectal Cancer; two Validation Study after In-Silico Analysis
  78. Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review
  79. Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients
  80. Gender Difference of Gastric Emptying in Healthy Volunteers and Patients with Functional Dyspepsia
  81. Bile Acids and Esophageal Cancer
  82. A simple scoring system to assess the need for an endoscopic intervention in suspected upper gastrointestinal bleeding: A prospective cohort study
  83. A prospective study on symptom generation according to spicy food intake and TRPV1 genotypes in functional dyspepsia patients
  84. Sa1711 The Presence of Sleep Disorders Was Independently Associated With Delayed Gastric Emptying, But Not With the Presence of Functional Dyspepsia
  85. Novel combination of serum microRNA for detecting breast cancer in the early stage
  86. Association of baseline plasma des-acyl ghrelin level with the response to rikkunshito in patients with functional dyspepsia
  87. Questionnaire-Based Survey on Diagnostic and Therapeutic Endoscopies and H. pylori Eradication for Elderly Patients in East Asian Countries
  88. Symptom Generation
  89. Influence of regular exercise on gastric emptying in healthy men: a pilot study
  90. Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies forHelicobacter pyloriStrains Containing thegyrAMutation
  91. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study
  92. Role of MicroRNAs-221/222 in Digestive Systems
  93. Association of Visceral Fat Area, Smoking, and Alcohol Consumption with Reflux Esophagitis and Barrett's Esophagus in Japan
  94. Faculty of 1000 evaluation for Association of Serum Levels of Adipokines and Insulin With Risk of Barrett's Esophagus: a Systematic Review and Meta-Analysis.
  95. Mo1405 The Aberrant Shape of Main Pancreatic Duct Increases the Risk of the Post ERCP Pancreatitis
  96. Sa1887 Adiponectin Ameliorates Carcinogenic Pathway Depending on miR-221/222 in Esophageal Adenocarcinoma Cells
  97. Sa1933 Overexpression of CD44v9 in Gastric Cancer Cells Confers Resistance to Trastuzumab by Inducing Antioxidant Enzymes That Inhibit Tumor Cell Death Induced by Oxidative Stress
  98. Sa1086 Smoking, a Previous History of Malignancy, and the Presence of Barrett's Esophagus As Risk Factors for Adenoma and Carcinoma of the Duodenum
  99. Nordihydroguaiaretic Acid Disrupts the Antioxidant Ability ofHelicobacter pylorithrough the Repression of SodB ActivityIn Vitro
  100. Faculty Opinions recommendation of High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity.
  101. Mucosal expression of aquaporin-4 in the stomach of histamine type 2 receptor knockout mice andHelicobacter pylori-infected mice
  102. Propofol versus traditional sedative agents for endoscopic submucosal dissection
  103. Sa1900 CD44v9 Results in Resistance to Trastuzumab via Induction of ROS Resistance
  104. 66 Neural Stem Cell Transplantation Restored the Delayed Gastric Emptying in Apolipoprotein E-Knockout Mice
  105. Sa1331 Efficacy and Safety of Rikkunshito, a Japanese Herbal Medicine, on the Treatment of Functional Dyspepsia: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study
  106. Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia-a multicenter, double-blind, randomized, placebo-controlled study
  107. MicroRNAs in Barrett's esophagus: future prospects
  108. Greater loss of productivity among Japanese workers with gastro-esophageal reflux disease (GERD) symptoms that persistvsresolve on medical therapy
  109. Small Cell Neuroendocrine Carcinoma of the Esophagus Producing Parathyroid Hormone-related Peptide with Humoral Hypercalcemia
  110. Bile Acids Increase Levels of MicroRNAs 221 and 222, Leading to Degradation of CDX2 During Esophageal Carcinogenesis
  111. Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial
  112. Correction: Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication
  113. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence
  114. Biliary Findings Assist in Predicting Enlargement of Intraductal Papillary Mucinous Neoplasms of the Pancreas
  115. Tu2095 Application of 13C-Acetic Acid Breath Test for Animals With Impaired Gastric Motility
  116. Tu1797 The Loss of Work Productivity Associated With Gastroesophageal Reflux Disease (GERD) in a Japanese Working Population
  117. Su1724 Expression of CD44 Variant 9 Contributes to 5-Fluorouracil Resistance in Gastric Cancer Through Anti-Oxidative Stress Mechanism
  118. Mo1849 Bile Acids Enhance Oncogenic miR-221/222 in the Transformation From Barrett's Esophagus to Adenocarcinoma
  119. Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan
  120. Enhancement of Amoxicillin Resistance after Unsuccessful Helicobacter pylori Eradication
  121. Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy
  122. Reactive Oxygen Species-Induced Autophagic Degradation of Helicobacter pylori CagA Is Specifically Suppressed in Cancer Stem-like Cells
  123. Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication
  124. Are Solifenacin and Ramosetron Really Ideal to Treat Irritable Bowel Syndrome?: Author's Reply
  125. The tumor suppressormicroRNA-29cis downregulated and restored by celecoxib in human gastric cancer cells
  126. Development of a novel microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs
  127. Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial
  128. High frequency of overlap between functional dyspepsia and overactive bladder
  129. Tu1155 The Extension of Mucosal Lesions, Helicobacter pylori Infection Status and API2-MALT1 Positivity are Associated With the Therapeutic Response for Gastric MALT Lymphoma
  130. Su1082 GERDQ is Superior Tool for the Evaluation of GERD Symptoms and Unmet Medical Needs to the Carlsson-Dent Questionnaire - a Large Scale Survey -
  131. Su1097 GERDQ is an Easy and Useful Tool for Assessing the Severity of Gastroesophageal Reflux Disease and Identifying Patients With “Unmet Medical Needs”
  132. Mo1569 MicroRNA-21 Expression Causes Nuclear Loss of the Tumor Suppressor PDCD4 in Precancerous Gastric Adenomas
  133. 616 Specific Amino Acid Mutation of p53 Enhanced the Stability of Intracellular CagA by Inhibiting Autophagy Induction
  134. Su1612 Dynamics of Aquaporin-4 in Gastric Parietal Cells in the Hyperplastic Gastric Fundic Mucosa of Histamine Type 2 Receptor Knockout Mice
  135. FecA1, a bacterial iron transporter, determines the survival of Helicobacter pylori in the stomach
  136. Reduced ghrelin production induced anorexia after rat gastric ischemia and reperfusion
  137. Classification of functional dyspepsia based on concomitant bowel symptoms
  138. Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies
  139. Helicobacter pylori Resistance to Rifabutin in the Last 7 Years
  140. Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy forHelicobacter pylorieradication?
  141. What Is the Difference Between -Associated Dyspepsia and Functional Dyspepsia?
  142. Enhancement of Amoxicillin Resistance after Unsuccessful Helicobacter pylori Eradication
  143. Dysfunctional Gastric Emptying With Down-regulation of Muscle-Specific MicroRNAs in Helicobacter pylori-Infected Mice
  144. Two Amino Acids Mutation of Ferric Uptake Regulator DeterminesHelicobacter pyloriResistance to Metronidazole
  145. Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in Helicobacter pylori
  146. Etiological difference between ultrashort- and short-segment Barrett’s esophagus
  147. Clinical results of observation of the upper gastrointestinal tract by transgastrostomic endoscopy using an ultrathin endoscope
  148. Serum lipid levels are positively associated with non-erosive reflux disease, but not with functional heartburn
  149. S1630 Caudal-Related Homeobox 2 (CDx2) Suppresses Stratification of Esophageal Squamous Epithelial Cells by Down-Regulating MicroRNA-221/222
  150. M1139 Sitafloxacin-Based Third-Line Eradication of H. pylori
  151. M1909 Increased Expression of MicroRNA-21 is an Early Event in Human Gastric Carcinogenesis
  152. 884 The Role of the Ferric Uptake Regulator (Fur) in Helicobacter pylori Resistance to Metronidazole
  153. S2063 Impaired Heme Oxygenase-1 Induction in the Gastric Antrum of Streptozotocin-Induced Diabetic Rats
  154. T1700 Dyslipidemia is a Risk Factor for NERD, but Not for Functional Heartburn
  155. T1766 Transient Gastroparesis and Reduced Ghrelin After Gastric Ischemia and Reperfusion
  156. 180 Induction of H. pylori Resistance to Metronidazole Through Enhanced Expression of a Bacterial Efflux Pump
  157. W1751 MicroRNA-21 Plays a Critical Role in Helicobacter pylori-Associated Gastric Cancer by Suppressing Btg2
  158. Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy
  159. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori
  160. Acid Suppression by Proton Pump Inhibitors Enhances Aquaporin-4 and KCNQ1 Expression in Gastric Fundic Parietal Cells in Mouse
  161. M1346 High Prevalence of Lower Gastrointestinal (GI) Symptoms in Functional Dyspepsia: A Factor and Cluster Analysis in the General Population
  162. 18 Overexpression of Mir-142-5p and Mir-155 and Suppression of Tumor Protein 53-Induced Nuclear Protein 1 in Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
  163. 266 Chronic Infection With Helicobacter pylori Induces Downregulation of Muscle-Specific MicroRNAs and Smooth Muscle Hypertrophy of the Mouse Stomach
  164. W1749 Downregulation of the Tumor Suppressor MicroRNA-29c Plays a Critical Role in the Progression of Human Gastric Cancer
  165. Ghrelin and oxidative stress in gastrointestinal tract
  166. Delayed gastric emptying and disruption of the interstitial cells of Cajal network after gastric ischaemia and reperfusion
  167. Gallstones increase the prevalence of Barrett’s esophagus
  168. Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells
  169. 977 Sitafloxacin and Garenoxacin, New-Generation Quinolones, Can Overcome the Antibiotic Resistance of H. pylori with gyrA Mutations
  170. M1051 Efflux Pumps Contribute to Clarithromycin Resistance in H. pylori
  171. 129 Ferric Uptake Regulator (FUR) Mutation in Helicobacter pylori Associated with the Development of Resistance to Metronidazole: Implication of the Structural-Functional Relationships of Mutant-Type Fur
  172. T1779 Enhanced Ghrelin Secretion and Gastric Excitatory Neural Network in Rats with Gastric Outlet Obstruction
  173. 47 Gastric Acid Secretion Suppression Enhanced Aquaporin-4 and KCNQ1 Expressions in the Fundic Parietal Cells
  174. W1953 MicroRNA-142 and -155 Are Novel Molecular Markers for Gastric MALT Lymphoma with API2-MALT1 FUSION
  175. 93 Enhanced Esophageal NADPH Oxidase 3 Expression and Free Radical Production in Response to Acid
  176. 1088 Role of MicroRNA-29c in the Chemoprevention of Gastric Cancer By a Selective COX-2 Inhibitor